Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 25;52(1):756.
doi: 10.1007/s11033-025-10862-z.

The effect of CYP3A4, CYP3A5 and MDR1 (ABCB1) single nucleotide polymorphisms on the pharmacokinetics of cyclosporine in Algerian stable renal transplant recipients

Maya Bouafia  1   2 , Mohamed El Amine Smaali  3 , Souheila Zemmouchi  4 , Ali Boumegoura  3 , Selwa Bellara  3 , Ayomide Victor Atoki  5 , Raid Serrar  6 , Khalid Bouhedjar  3 , Mohammed Messaoudi  7 , Noureddine Abadi  8 , Mohamed Habib Belmahi  2
Affiliations

The effect of CYP3A4, CYP3A5 and MDR1 (ABCB1) single nucleotide polymorphisms on the pharmacokinetics of cyclosporine in Algerian stable renal transplant recipients

Maya Bouafia et al. Mol Biol Rep. .

Abstract

Background: Cyclosporine (CsA) is a calcineurin inhibitor (CNI) commonly prescribed after organ transplantation to reduce the risk of graft rejection and prolong both graft and patient survival. However, its clinical use is often limited by a narrow therapeutic index and highly variable, unpredictable pharmacokinetics. Consequently, close therapeutic monitoring is essential to ensure effective immunosuppression. Genetic polymorphisms in cytochrome P450 3 A (CYP3A) enzymes and the multidrug resistance gene 1 (ABCB1) may influence CsA dose requirements and blood concentrations in renal transplant recipients.

Methods and results: This study aimed to evaluate the impact of selected single nucleotide polymorphisms (SNPs) in CYP3A4, CYP3A5, and ABCB1 genes in a cohort of Algerian renal transplant patients. Fifty stable kidney transplant recipients were enrolled. SNPs of CYP3A4, CYP3A5 and ABCB1 genes were detected with direct sequencing and associations between genotypes and CsA dose requirements, trough concentrations (C₀), 2 h post dose concentration (C2) and dose-adjusted trough levels (C/D) were investigated. A significant decrease of CsA trough concentration C0 and C0/D ratio was observed in the carriers of the heterozygote genotype CYP3A5*1/3 against homozygote ones CYP3A53/*3 (43.86 ± 16.53 vs. 58.21 ± 24.31 ng/mL per mg per kg); p = 0.039. Moreover, the CYP3A5 *1/3 genotype was associated with significantly lower cholesterol levels compared to patients carrying the CYP3A53/*3 genotype (14.20 ± 10.66 vs. 33.11 ± 20.69); p = 0.0002. In contrast, the ABCB1 3435 C > T polymorphism (C/C, C/T, or T/T genotypes) showed no significant association with CsA pharmacokinetics.

Conclusions: In conclusion, the CYP3A5 A6986G (*3/*3) polymorphism is significantly associated with higher CsA trough levels and dose-adjusted concentrations, as well as increased cholesterol levels in stable renal transplant recipients even with similar doses. Conversely, variability in CsA pharmacokinetics does not appear to be significantly influenced by ABCB1 3435 C > T polymorphisms.

Keywords: ABCB1; CYP3A; Cyclosporine; Personalized therapy; Pharmacokinetics; Polymorphism; Renal transplant recipients.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: The study protocol was reviewed and approved by the Ethics Committee of Dr. Benbadis University Hospital Center, Constantine (Reference No. CE/CHUC/07/01-2019). All procedures involving human participants were conducted in strict accordance with the ethical standards of the Declaration of Helsinki. Consent to participate: All authors approved. Consent for publication: All authors agree to the publication. Informed consent: Written informed consent was obtained from all participants before inclusion in the study. Competing interests: The authors declare no competing interests.

Similar articles

See all similar articles

References

    1. Wei JYX, Gao J, Wang C, Wei W et al (2023) Role of cyclosporin A in the treatment of kidney disease and nephrotoxicity. Toxicology 492:153–544
    1. Sun B, Guo Y, Gao J, Shi W, Fan C, Li X, Qiu J, Qin Y, Liu G et al (2017) Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients. Pharmacogenomics 18:1503–1513 - PubMed
    1. Kasiske BL, Zeier MG, Chapman RJ, Craig CJ, Ekberg H, Garvey AC, Green MD, Jha V, Josephson MA, Kiberd BA, Kreis HA, McDonald RA, Newmann JM, Obrador GT, Vincenti FG, Cheung M, Earley A, Raman G, Abariga S, Balk EM et al (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 77:299–311 - PubMed
    1. Rodrigo E, Ruiz J, De Cos MA, Rui J, Gago M, Piñera C, Sánchez B, González-Cotorruelo J, Gómez-Alamillo C, Arias M et al (2009) Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation. Transpl Proc 41:2328–2331
    1. Kong Q, Gao N, Wang Y, Hu G, Qian J, Chen B et al (2023) Functional evaluation of cyclosporine metabolism by CYP3A4 variants and potential drug interactions. Front Pharmacol 13

LinkOut - more resources